Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis
30 juin 2023 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
Madrigal expects to complete full submission of the New Drug Application in July 2023 CONSHOHOCKEN, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a...
Madrigal Pharmaceuticals Presents Phase 3 MAESTRO-NASH Data During the Opening General Session of the EASL Congress™
22 juin 2023 03h30 HE
|
Madrigal Pharmaceuticals, Inc.
First scientific presentation of detailed MAESTRO-NASH results confirms achievement of primary endpoints across multiple patient subgroupsNoninvasive imaging and biomarker data support findings on...
Growth in Patient and Medical Community Engagement in NASH Community Persists Despite Recent Regulatory Disappointment
08 juin 2023 07h19 HE
|
Global Liver Institute
Washington, D.C., June 08, 2023 (GLOBE NEWSWIRE) -- Today is International NASH Day, a time where healthcare experts and community members around the globe step up and raise awareness of the most...
Inventiva et Echosens lancent une initiative conjointe pour mieux sensibiliser l’opinion à la NASH et faciliter l’accès au dépistage pour les patients à risque
08 juin 2023 02h30 HE
|
INVENTIVA
Daix (France) et Long Island City (New York, Etats-Unis), Paris (France) et Waltham (Etats-Unis), le 8 juin 2023 - Inventiva (Euronext Paris et Nasdaq : IVA) (la « Société »), société...
Inventiva and Echosens launch joint initiative to increase NASH awareness and access to screening for at-risk patients
08 juin 2023 02h30 HE
|
INVENTIVA
Daix (France), Long Island City (New York, United States) / Paris (France) and Waltham (United States), June 8, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage...
Inventiva annonce cinq présentations scientifiques lors de l’EASL International Liver Congress™ 2023
07 juin 2023 16h00 HE
|
INVENTIVA
Cinq présentations par poster démontrant : La corrélation entre l'amélioration de la stéatose hépatique et une forte augmentation du taux d'adiponectine, l’amélioration du profil lipidique et du...
Inventiva announces five scientific presentations at the EASL International Liver Congress™ 2023
07 juin 2023 16h00 HE
|
INVENTIVA
Five poster presentations showing : the correlation between the improvement of hepatic steatosis and a robust increase in adiponectin levels, improvement in lipid profile and glycemic control in...
Sagimet Biosciences to Present Interim Data from Phase 2b Trial of Denifanstat in NASH at EASL Congress 2023
07 juin 2023 09h00 HE
|
Sagimet Biosciences Inc.
SAN MATEO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways,...
Madrigal Pharmaceuticals Supports International NASH Day on June 8
06 juin 2023 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., June 06, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
01 juin 2023 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., June 01, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...